Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | terminated | Phase 2 | 35 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05081180 | Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | terminated | Phase 1 | 17 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 4 | Jul 29, 2026 |
| clinicaltrials |
| NCT05322577 | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.(FORTITUDE-103) | terminated | Phase 1 / Phase 2 | 72 | AmgenINDUSTRY | 5 | Jul 29, 2026 | clinicaltrials |
| NCT06622226 | A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | terminated | Phase 1 | 2 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT03598608 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | terminated | Phase 1 / Phase 2 | 137 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Jul 28, 2026 | clinicaltrials |
| NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | terminated | Phase 2 | 7 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05616624 | ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers | terminated | Phase 1 / Phase 2 | 31 | Washington University School of MedicineOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05754749 | Comparison of CE-DBT and MRI in Patients With Known Breast Lesions | terminated | Early Phase 1 | 4 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT03835273 | Oesophagectomy and Chest Wall and Respiratory Function | terminated | — | 73 | Imperial College LondonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03941366 | Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders | terminated | N/A | 15 | Henry Ford Health SystemOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | terminated | Phase 1 / Phase 2 | 179 | GenmabINDUSTRY | 9 | Jul 23, 2026 | clinicaltrials |
| NCT05526079 | Watchful Waiting for Complete Responders to Therapy in Rectal Cancer | terminated | N/A | 15 | Henry Ford Health SystemOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05714553 | NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 19 | NuCana plcOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06008483 | A Dose Finding Study to Treat Bone Tumor(s) | terminated | Phase 1 | 5 | QSAM Therapeutics, Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06022757 | Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19) | terminated | Phase 1 / Phase 2 | 12 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT00788307 | Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy | terminated | Phase 1 | 8 | Mayo ClinicOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02546986 | Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | terminated | Phase 2 | 100 | CelgeneINDUSTRY | 6 | Jul 22, 2026 | clinicaltrials |
| NCT03786081 | Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer | terminated | Phase 1 / Phase 2 | 214 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT04461509 | High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | terminated | Phase 2 | 62 | Alessandro D'AgnoloOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05689021 | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | terminated | Phase 2 | 8 | Mayo ClinicOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03445000 | ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer(ALERT-lung) | terminated | Phase 2 | 14 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jul 21, 2026 | clinicaltrials |
| NCT05026736 | Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer(ELONA) | terminated | Phase 1 / Phase 2 | 4 | Context Therapeutics Inc.INDUSTRY | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05823467 | What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery | terminated | N/A | 4 | University of AlbertaOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT00707473 | Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer | terminated | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02967276 | Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma(METDEXA-MM) | terminated | Phase 2 | 28 | University of Campinas, BrazilOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT01523171 | Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib(JAKARTA2) | terminated | Phase 2 | 97 | Bristol-Myers SquibbINDUSTRY | 10 | Jul 16, 2026 | clinicaltrials |
| NCT03148327 | Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy | terminated | Phase 1 / Phase 2 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05875935 | Assessment of Awake Surgery With Electrocorticographic Recordings in the Management of Gliomas and Correlation With Imaging Data (ECoG)(ECoG) | terminated | N/A | 1 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06028373 | A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas | terminated | Phase 1 | 38 | Antengene Biologics LimitedINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma(BATTMAN) | terminated | Phase 3 | 21 | Canadian Cancer Trials GroupNETWORK | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07441330 | Evaluation of Data Obtained From Three Common Imaging Techniques: Positron Emission Tomography (PET-CT), Breast Ultrasound, and Magnetic Resonance Imaging (MRI) After Neoadjuvant Chemotherapy in Patients With Breast Cancer | terminated | N/A | 42 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04698564 | Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging | terminated | Phase 2 | 4 | University of Maryland, BaltimoreOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06528093 | A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy | terminated | Phase 1 | 8 | Boehringer IngelheimINDUSTRY | 6 | Jul 15, 2026 | clinicaltrials |
| NCT04469504 | Preoperative Prehabilitation for Sarcopenic Patients Prior to Pancreatic Surgery for Cancer(PSOAS) | terminated | N/A | 6 | University Hospital, LilleOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT02200042 | Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer | terminated | Phase 3 | 1 | NRG OncologyOTHER | 2 | Jul 13, 2026 | clinicaltrials |
| NCT03874858 | A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia(DANTE) | terminated | Phase 2 | 135 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04933695 | A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment(CodeBreaK201) | terminated | Phase 2 | 42 | AmgenINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT05067777 | Massage for Prostate Cancer-Related Fatigue (mPROSTATE)(mPROSTATE) | terminated | Phase 2 | 28 | University of UtahOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05451849 | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer | terminated | Phase 1 / Phase 2 | 14 | TCR2 TherapeuticsINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma(PNOC018) | terminated | Phase 1 | 4 | University of California, San FranciscoOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06158100 | Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | terminated | Phase 1 | 2 | Antonio M Jimenez JimenezOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06470451 | Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL(FLASH2) | terminated | Phase 3 | 70 | SoligenixINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03439046 | Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant(BioItaLEE) | terminated | Phase 3 | 287 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03766126 | Lentivirally Redirected CD123 Autologous T Cells in AML | terminated | Phase 1 | 22 | University of PennsylvaniaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 29, 2026source: clinicaltrials